Guardant Health Enhances Workforce with New Equity Awards for Talent Attraction and Retention

Guardant Health Strengthens Workforce with New Equity Awards

On October 22, 2024, Guardant Health, Inc., a leader in precision oncology, announces a strategic move to enhance its workforce by approving a significant number of restricted stock units (RSUs) and non-qualified stock options for new non-executive employees. This initiative, involving 233,603 RSUs and 50,349 stock options, is part of the company’s 2023 Employment Inducement Incentive Award Plan. Designed specifically for individuals who are new to the company or those returning after a bona fide non-employment period, this plan adheres to the Nasdaq Listing Rule 5635(c)(4), highlighting Guardant’s commitment to attracting top talent in the competitive oncology landscape.

The RSUs awarded will vest annually, with one-third of the shares becoming available on each anniversary of the commencement date, contingent upon the employee's continued employment. This structured vesting schedule aims to retain skilled professionals and align their interests with the long-term goals of the company. The non-qualified stock options come with an exercise price set at $28.16 per share, reflecting the closing price of Guardant's stock on the Nasdaq Global Select Market on the grant date. The stock options will also follow a staggered vesting approach, with one-third vesting after one year and the remainder vesting monthly over the subsequent 24 months.

Guardant Health, founded in 2012, focuses on improving patient outcomes through its innovative blood and tissue tests, real-world data, and AI analytics. The company’s mission is to enhance cancer detection, monitoring, and treatment selection, making significant strides in personalized medicine. By investing in its workforce through these equity awards, Guardant Health not only fortifies its talent pool but also reinforces its commitment to advancing cancer care, ensuring that it remains at the forefront of precision oncology.

In addition to this workforce expansion, Guardant Health continues to engage with its community through various social media platforms, including LinkedIn, X (Twitter), and Facebook. The company’s dedication to transparency and communication is evident as it shares updates and insights about its groundbreaking work in oncology.

For more information about Guardant Health’s innovative solutions and initiatives in the oncology field, interested parties can visit their official website at guardanthealth.com.